Researchers based at the Singapore National Eye Center have reported their findings on a novel “deep learning system” (DLS) – a machine learning technology with… Read More »Artificial intelligence technology provides potentially promising tool for diabetic retinopathy screening.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 19th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »December 19th, 2017: “EURETINA-Brief”© Issue No. 167
Novartis AG (NYSE:NVS; SIX:NOVN) has announced additional data form their Phase III HAWK and HARRIER trials of brolucizumab (RTH258) for the treatment of wet AMD.… Read More »Competition for anti-VEGF market heats up with release of additional Phase III data from Novartis on new wet AMD treatment
Positive preliminary findings have been reported from Phase I and Phase 2 clinical research using retinal pigment epithelial (RPE) cells derived from embryonic stem cells.… Read More »Stem cell therapy clinical trial demonstrates safety and potential efficacy in small numbers of patients
Researchers based at New York University School of Medicine have published research confirming an association between subretinal drusenoid deposits (SDD) and macular atrophy (MA) in… Read More »Macular atrophy development in patients treated with anti-VEGFs show a clear association with subretinal drusenoid deposits.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 4th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »December 4th, 2017: “EURETINA-Brief”© Issue No. 166
A new gene therapy for the treatment of Leber’s congenital amaurosis (LCA) is predicted to be priced at somewhere between $650,000 and $1,000,000 per patient… Read More »New gene therapy for inherited blindness could cost patients up to $1m per treatment
A new antibody drug (lampalizumab) targeting geographic atrophy in age related macular degeneration has missed its primary endpoint in two pivotal Phase III studies comprising… Read More »New geographic atrophy drug for AMD fails to meet primary endpoint in age-related macular degeneration
A Spanish research team, based at the Instituto de Investigación Sanitaria La Fe (IIS La Fe), Valencia, have published data showing preliminary proof-of-principle for the… Read More »Spanish research suggests gene editing may provide a potential treatment for Usher’s syndrome.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the November 17th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »November 17th, 2017: “EURETINA-Brief”© Issue No. 165